ProMOTE: the prognostic markers of TIA evolution.
Meetings and Proceedings
ProMOTE aims to determine the predictive power of microalbuminuria after a Transient Ischemic Attack (TIA) or minor stroke. In a pilot study of 150 patients it was demonstrated that in some patients this protein was higher in those who went on to have a full stroke after a TIA. Further to the success of the pilot study, ProMOTE will recruit 2400 participants over two years to determine whether the urinary Albumin Creatinine Ratio (ACR) represents a significant prognostic indicator independent of conventional risk factors at a much lower value than is currently deemed “abnormal”. The pilot study data suggests microcirculatory dysfunction, as assessed by ACR, is not only a marker of unmeasured risk, but may also represent an untreated therapeutic target after stroke. ProMOTE will determine the predictive utility of ACR as a currently un-established therapeutic target post stroke or TIA. The success of ProMOTE could influence stroke care by helping doctors decide which patients would benefit from more intensive hospital treatment and those who could be discharged; reducing rates of completed stroke and preventing unnecessary admissions.